Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention

NCT06413095 is registered in ClinicalTrials.gov with Presage Biosciences as lead sponsor.

NCT NCT06413095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06413095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention
Lead sponsor
Presage Biosciences
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2022
Completion date
June 22, 2023
Enrollment
13 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, soft tissue sarcoma